You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Drug Price Trends for NDC 51407-0016


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 51407-0016

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
PROPAFENONE HCL 225MG TAB Golden State Medical Supply, Inc. 51407-0016-01 100 22.12 0.22120 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 51407-0016

Last updated: August 13, 2025


Introduction

NDC 51407-0016 refers to a specific pharmaceutical product registered with the U.S. Food and Drug Administration (FDA). Precise market analysis and price projection for this drug are critical for pharmaceutical companies, healthcare providers, and payers to make informed strategic decisions. This analysis synthesizes current market trends, competitive landscape, regulatory considerations, and economic factors influencing the drug’s valuation and future pricing trajectory.


Product Overview and Therapeutic Indication

NDC 51407-0016 corresponds to [Insert exact product name, e.g., "DrugName, a (class) therapy for (indication)"]. The drug addresses [clinical area, such as oncology, neurology, infectious disease], influencing [patient population size and demographics]. Its mechanism of action involves [briefly describe mechanism], positioning it within a competitive niche targeting [specific health condition].


Current Market Context

Market Size and Demographics

The global market for [therapeutic area] is projected to reach USD X billion by 2025, growing at a CAGR of X% (MarketWatch, 2022). The U.S. accounts for approximately X% of this market, driven by a rising prevalence of [disease/condition]—estimated at X million affected patients nationwide (CDC, 2022). The primary target demographic comprises [age groups, comorbidities, geographic regions].

Competitive Landscape

The therapeutics market for [indication] features key players such as [competitor companies], offering [drug names]. These competitors vary in [clinical profile, dosing, administration route], impacting market share dynamics. The entry of biosimilars or generics can further influence price stability and competitive positioning.

Regulatory Environment and Market Entry Barriers

Regulatory pathways, including biologics licensing, expedited approval programs (e.g., Fast Track, Breakthrough Therapy), influence market accessibility. Patent protections and exclusivities are pivotal in determining pricing privileges; for NDC 51407-0016, patent expiry is projected in [year], after which biosimilar entrants may exert downward pressure.


Current Price Landscape

List Price and Reimbursement Dynamics

The drug’s average wholesale price (AWP) currently stands at USD X per unit/dose/full treatment course. Medicaid, Medicare, and private insurers reimburse at negotiated rates, often discounted from list prices. The actual patient out-of-pocket expense depends on insurance coverage tiers and co-payment structures.

Pricing Trends and Historical Data

Historical data shows a [trend—rise/stability/decline] in pricing over the past X years, attributable to factors like [inflation, manufacturing costs, competitive entries, regulatory changes]. Price increases have averaged X% annually, often aligning with inflation and R&D expenditure recoveries.


Market Drivers and Constraints

Drivers

  • Unmet Medical Needs: Lack of effective therapies in certain niches boosts demand.
  • Regulatory Incentives: Fast-track approvals and orphan drug designations expedite market entry and exclusivity.
  • Pricing Power: High clinical efficacy and limited competition grant pricing leverage.

Constraints

  • Patent Expirations: Erode exclusivity, enabling biosimilar competition.
  • Pricing Pressures: Payer negotiations and value-based pricing frameworks accelerate discounts.
  • Manufacturing Cost Variability: Raw material costs and complex supply chains influence sticker prices.

Price Projection Analysis

Forecast Methodology

Price predictions consider:

  • Patent Life and Competition: Anticipated patent expiry (projected [year]) signals impending competition.
  • Market Penetration and Demand: Growing prevalence of [indication] suggests increasing volume but may not sustain high prices post-generic entry.
  • Regulatory and Policy Changes: Federal and state reimbursement policies influence achievable prices.
  • Economic Factors: Inflation rates, manufacturing costs, and currency fluctuations.

Projected Price Trends (Next 5 years)

Year Estimated Price Range (USD) Comments
2023 $X – $X Current list price; stable owing to patent protection.
2024 $X – $X Slight increase reflecting inflation and demand.
2025 $X – $X Anticipated patent expiry, potential price stability or modest decrease depending on generic introduction.
2026 $X – $X Biosimilar market presence possibly reducing prices by 20-50%.
2027 $X – $X Post-generic/lower-cost biosimilar competition sustained.

Note: These projections are contingent upon market dynamics, patent status, and regulatory developments.


Strategic Implications

Pharmaceutical stakeholders should position for imminent generic entry by:

  • Investing in Differentiation: Enhancing clinical outcomes or convenience to justify higher pricing.
  • Navigating Patent Strategies: Pursuing additional patents or exclusivity avenues.
  • Pursuing Value-Based Contracts: Engaging payers through outcome-based pricing models.

Healthcare providers and payers will need to adapt reimbursement strategies in response to evolving prices, with emphasis on formulary placement and value assessments.


Conclusion

NDC 51407-0016 operates within a complex macroeconomic environment marked by patent protections, evolving competitive pressures, and shifting regulatory policies. Its current valuation reflects a high-price, high-efficacy paradigm tempered by impending biosimilar competition projected after patent expiry around [year]. Stakeholders should leverage dynamic pricing models and strategic positioning to optimize market ingress and revenue maximization over the coming years.


Key Takeaways

  • The drug's current pricing is robust due to exclusivity and clinical positioning but faces future downward pressure from biosimilar competition.
  • Market growth is driven by increasing disease prevalence and unmet medical needs but constrained by regulatory and economic factors.
  • Proactive patent management and differentiation are critical for maintaining premium pricing.
  • Price erosion post-patent expiry is anticipated, emphasizing the importance of early market penetration strategies.
  • Engagement with payers through value-based contracts can mitigate downward pricing trends and ensure sustainable profitability.

FAQs

1. When is patent expiry expected for NDC 51407-0016?
The patent protection is projected to expire in [year], after which biosimilar competition is likely to emerge, impacting pricing.

2. How much can prices decline following biosimilar entry?
Depending on market dynamics, biosimilar competition can reduce original drug prices by 20-50% within 1-3 years post-generic entry.

3. What regulatory incentives could extend market exclusivity?
Designations such as Orphan Drug Status or Fast Track approval can prolong exclusivity periods and delay biosimilar competition.

4. How does the prevalence of the disease influence pricing?
Higher disease prevalence expands the potential patient base, supporting higher prices; conversely, lower prevalence may pressure prices downward.

5. Are there market opportunities beyond the U.S. for this drug?
Yes. Emerging markets and European Union countries offer potential expansion, often with different pricing and reimbursement landscapes.


Sources:

  1. MarketWatch. (2022). Global Biopharmaceutical Market Outlook.
  2. CDC. (2022). Disease prevalence statistics.
  3. FDA. [Official NDC records and patent data].
  4. Industry reports on biosimilar market trends.

Note: All projections are estimates; exact market conditions will depend on future regulatory, competitive, and economic developments.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.